Inhibition of platelet aggregation by medermycin and it's related isochromanequinone antibiotics.

Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum

“…Nanaomycin A 41,42 is another pyranonaphthoquinone natural product of significant interest in our laboratory due to its wide range of biological activity, 41,43,44 however to the best of our knowledge it has not been screened for topoisomerase II inhibition. Our recent synthetic efforts towards nanaomycin A resulted in the enantioselective synthesis of a 1,3-cis analogue of deoxynanaomycin A (+)-13 45 using an asymmetric allylation as the key step.…”

Bioactive C-Glycosides from Bacterial Secondary Metabolism

“…In addition to their antibiotic and antitumour activities, medermycin and some related BIQ compounds are modest inhibitors of induced platelet aggregation. Medermycin inhibited ADP-, thrombin-, and arachidonic acid-induced aggregation of platelet-rich plasma with IC 50 values of 5, 6, and 100 mg/mL, respectively [53].…”

Synthesis of triazole analogues of the nanaomycin antibiotics using ‘click chemistry’

“…4e9 In addition, nanaomycin A 1 has been shown to inhibit the platelet aggregation agent, adenosine diphosphate (ADP). 10 Furthermore, fermentation of a Nocardia species produced YS-02931K-b 6, the enantiomer of nanaomycin A 1. Compound 6 exhibited strong antimicrobial activity against Gram-positive bacteria as well as dermaphytes and fungi.…”